A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published in the 12 February 2015 issue of the Journal “Cell” [I.F:33] by Drs. Alberto Mantovani , Eduardo Bonavita and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Inflammation-mediated cancers: Luteolin, a flavone found in celery, green peppers, and chamomile tea, increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene. Thus, pharmacological formulations encompassing “Luteolin or its analogues” may be used to treat patients suffering from inflammation-mediated tumorigenesis.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for Inflammation-mediated cancers: Luteolin increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene, 11/March/2015, 11.57 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Luteolin increases the expression of PTX3